reports
- Robert Sassoon
Water Tower Hour Recap: BayMedica's Jerry Griffin on Why Rare Cannabin...
BayMedica’s VP, Sales & Marketing, Jerry. P. Griffin joined us on The Water Tower Hour. Those interested can listen to the podcast on Apple Podcasts, Google Podcasts, Spotify, or our website. BayMedica is the commercial business arm of rare cannabinoids-based drug developer InMed Pharmaceuticals. BayMedica sells high purity and consistent rare cannabinoid ingredients to the health and wellness sector. Its business has quickly increased its annual revenue to more than $5 million. Explaining rare ...
- Robert Sassoon
Revenues Flowing, Drug Development Pipeline Advancing
2QFY24 Review BayMedica reports another strong quarter. The commercial business operating arm of InMed reported revenue of $1.24 million for the quarter ended December 30, 2023, representing a 164% Y/Y increase and 38% Q/Q growth. Revenue for the quarter exceeded our estimate of $1.13 million. BayMedica has now recorded quarterly revenue of more than $1 million in three of the last four quarters. For the first six months of the current fiscal year ending June 30, 2024, revenue climbed 171% to $2...
- Robert Sassoon
Opportunity-Rich Pharmaceuticals Pipeline
Water Tower Research hosted InMed’s CEO and President Eric. A. Adams for a fireside chat on January 25, 2024. The discussion, hosted by Jesse Redmond, Managing Director at Water Tower Research, focused on InMed’s pharmaceutical pipeline in Alzheimer’s and age-related macular degeneration (AMD) and upcoming 2024 milestones in both its pharmaceutical drug development programs and in BayMedica’s health and wellness initiatives. This report contains a transcript of the conversation, which can be acc...
- Robert Sassoon
Strategic Priorities Laid Out for 2024
Building on a year of progress. Following a banner year for InMed in 2023, including significant advancement and expansion of its rare cannabinoids-focused pharmaceuticals development programs and a breakout year for BayMedica’s commercial operations, the company has laid out its strategic priorities for 2024. We will be hosting a fireside chat with CEO and President Eric A. Adams on January 25, 2024, at 1:00 pm ET. Registration link is available in our full report. Advancing a potentially novel...
- Robert Sassoon
Expands Ocular Disease Treatment Pipeline
Unveiling INM-089 targeting AMD. InMed is expanding its rare cannabinoid cannabinol (CBN)-based ocular disease treatment pipeline with INM-089, targeting age-related macular degeneration (AMD). INM-089, a CBN analog, is InMed’s second ocular pharmaceutical program, with the company currently engaged in pre-clinical studies of INM-088, investigating its effects in the treatment of glaucoma. InMed’s ocular programs target leading causes of severe eyesight loss and blindness. Glaucoma is the second...
- Robert Sassoon
1QFY24 Review: Pharmaceutical Advances Continue
1QFY24 Review BayMedica registers strong Y/Y growth. Although BayMedica reported a 61% decline in sequential revenue in the opening quarter of its new fiscal year ending June 30, 2024, the $902K in sales reported for 1QFY24 was nevertheless almost triple the $321K generated in the year-ago quarter. The immaturity of rare cannabinoids ingredients market for health & wellness products makes it difficult to determine definitively any seasonality in the business. However, it should not go unnoticed ...
- Robert Sassoon
Unveiling INM-901
InMed completes the screening process in its neurodegenerative diseases program. InMed took a significant step forward in its INM-900 series program after confirming that it has made its final selection of a lead Alzheimer’s disease drug candidate. InMed launched the program in November 2022, targeting the use of proprietary cannabinoid analogs to treat neurodegenerative diseases after its research had identified two promising cannabinoid analog candidates warranting further investigation in in ...
- Robert Sassoon
4QFY23 Review; Progress on All Fronts
4QFY23 Review BayMedica continues impressive growth. As had already been signaled in an early disclosure filing in July, InMed’s BayMedica subsidiary delivered $2.3 million of revenue for the final quarter of its fiscal year ended June 30, 2023. This represents 124% sequential revenue growth over the preceding quarter following sequential revenue growth of 46% and 120% recorded for 2QFY23 and 3QFY23, respectively. The full fiscal year 2023 revenue total exceeded $4.1 million. This growth profile...
- Robert Sassoon
White Paper Highlights Attributes of CBC
Therapeutic attributes of CBC highlighted in white paper. InMed Pharmaceuticals’ commercial subsidiary BayMedica released a white paper, which collates a curated collection of scientific research on the physiological and potential therapeutic effects of cannabichromene (CBC). CBC is BayMedica’s lead product sold to the health & wellness sector. The BayMedica white paper can be accessed in our full report by accessing the link below. CBC demonstrates potent anti-inflammatory effects. Since the di...
- Robert Sassoon
A Massive Market Opportunity
Water Tower Research hosted InMed’s BayMedica VP, Sales & Marketing Jerry P. Griffin for a fireside chat on July 25. Our chat included an overview of the BayMedica business and its competitive environment; the market dynamics of rare cannabinoids and their disruptive potential in the health & wellness sector; and upcoming catalysts for BayMedica. This report contains a transcript of the conversation, which can be accessed on demand and in the full report. Rare cannabinoids in demand. Although st...
- Robert Sassoon
InMed Signals Another Super Quarter for BayMedica
BayMedica’s exponential growth momentum continues. This morning, InMed Pharmaceuticals (INM) provided a business update on the progress of its BayMedica subsidiary, a leading supplier of rare non-psychoactive cannabinoids to the health & wellness sector. In an early disclosure, ahead of a formal release of InMed’s 4QFY23 earnings, expected in September, the company signaled that BayMedica will report a 123% q-o-q surge in revenues to more than $2.3M for the fiscal fourth quarter ended June 30, 2...
- Robert Sassoon
INM-755 Phase II Data Support a Clear Pathway to Further Development
The bottom line from the INM-755 Phase II study’s top-line results. InMed published top-line data for its most advanced drug development program, INM-755, a cannabinol (CBN)-based topical skin cream to treat symptoms associated with a rare genetic dermatological condition called epidermolysis bullosa (EB). Using a wide lens approach, the Phase II study produced sufficient clinically important chronic itch relief data to support a pathway to further development and potentially bigger commercial o...
- Robert Sassoon
In a Good Place
Water Tower Research hosted InMed's CEO and President Eric A. Adams for a fireside chat on May 23. Our discussion included an overview of rare cannabinoids, InMed's pharmaceutical development programs, the importance of its BayMedica subsidiary, the company's financing strategy, and upcoming catalysts. This report contains a transcript of the conversation, which can be accessed on demand. InMed is a rare cannabinoids company, not a cannabis company. While rare cannabinoids are typically associat...
- Robert Sassoon
Delivers Strong 3QFY23 Revenue Growth; Confirms Progress in Pharmaceut...
3QFY23 Review BayMedica's best revenue growth quarter yet. InMed's BayMedica subsidiary, which supplies non-psychoactive rare cannabinoid products to the heath & wellness sector, delivered its best revenue quarter yet since being acquired in October 2021. InMed's third quarter for its fiscal year ending June 30, 2023, saw revenue from the rare cannabinoids business surge 120% from the previous quarter and more than triple from the year-ago period, breaking the $1 million barrier for the first ti...
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provide...
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update Closed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and...
InMed Submits Form 12b-25
InMed Submits Form 12b-25 VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces it has submitted a Form 12b-25 with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “Form 10-Q”). Due to the recent change in the Company’s auditors as previously announced on December 12, 2022 and ...
InMed Provides Business Update and Milestones for 2023
InMed Provides Business Update and Milestones for 2023 Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today out...
InMed Announces Results of 2022 Annual General Meeting
InMed Announces Results of 2022 Annual General Meeting VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 15, 2022 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 28, 202...
InMed Announces Appointment of Interim Chief Financial Officer and Cha...
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the “Contract”) with Brio Financial Group (“Brio”) to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the ...
InMed Pharmaceuticals Announces Closing of $6 Million Private Placemen...
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of its common shares at a purchase price of $3.30 per share (or pre-funded warr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.